Highly Sensitive Detection of Anti-SARS-CoV-2 Antibodies in Human Serum Using Bloch Surface Wave Biosensor
Accurate and sensitive antibody detection remains critical for advanced COVID-19 diagnostics and monitoring SARS-CoV-2 immunity. This study presents a highly sensitive technique for detecting anti-SARS-CoV-2 antibodies in human serum using an integrated photonic sensing platform. The platform utilizes disposable one-dimensional photonic crystal biochips engineered to sustain Bloch Surface Waves. The biochips are integrated into a custom-made optical set-up, which is capable of dual-mode detection: label-free refractometry and label-based fluorescence. Tests on human serum, including negative controls and positive samples from a recovered COVID-19 patient, confirmed the platform's effective performance. In fluorescence mode, clear discrimination between positive and negative samples was achieved down to a 1:10<sup>4</sup> serum dilution, with an optimal operating range centered around 1:10<sup>3</sup> dilution. These results demonstrate the potential of the technique as a highly sensitive and versatile platform for antibody detection, with significant relevance for advanced COVID-19 diagnostics.
Authors
- Alberto Sinibaldi (ORCID: https://orcid.org/0000-0003-1970-3737)
- Matteo Allegretti (ORCID: https://orcid.org/0000-0003-3398-8775)
- Paola Di Matteo (ORCID: https://orcid.org/0000-0001-8837-6317)
- Agostino Occhicone (ORCID: https://orcid.org/0000-0001-8295-6222)
- Chiara Mandoj
- Daniele Chiappetta
- Norbert Danz (ORCID: https://orcid.org/0000-0002-8927-9284)
- Peter Munzert
- F. Michelotti
- Anastasiia Gaganina
Institutions
- Fraunhofer Institute for Applied Optics and Precision Engineering (DE)
- National Cancer Institute (MY)
- Center for Nano Science and Technology (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Sensors
- Published
- 2025-12-20
- DOI
- https://doi.org/10.3390/s26010046
- Primary Topic
- Photonic and Optical Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission